News
ADAG
3.820
+0.26%
0.010
Weekly Report: what happened at ADAG last week (0406-0410)?
Weekly Report · 2d ago
Adagene Inc. - Depositary Receipt (ADAG) Price Target Increased by 11.46% to 11.57
NASDAQ · 04/09 03:43
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/08 17:05
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG), Caribou Biosciences (CRBU) and Praxis Precision Medicines (PRAX)
TipRanks · 04/07 10:10
Guggenheim Keeps Their Buy Rating on Adagene (ADAG)
TipRanks · 04/06 16:36
Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program
TipRanks · 04/06 13:15
Adagene Is Maintained at Buy by Guggenheim
Dow Jones · 04/06 12:05
Guggenheim Maintains Buy on Adagene, Raises Price Target to $10
Benzinga · 04/06 11:55
Adagene price target raised to $10 from $9 at Guggenheim
TipRanks · 04/06 10:45
Weekly Report: what happened at ADAG last week (0330-0403)?
Weekly Report · 04/06 10:18
Adagene announces pricing of $70M public offering of ADS
Seeking Alpha · 04/02 12:40
Adagene 18.666M share Spot Secondary priced at $3.75
TipRanks · 04/02 12:14
Adagene enters pact with Incyte for combination of muzastotug, INCA33890
TipRanks · 04/02 12:01
Adagene announces results from the latest data cut of muzastotug study
TipRanks · 04/02 11:55
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer
TipRanks · 04/02 11:38
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline
TipRanks · 04/02 11:36
Adagene sets $3.75 per ADS price for $70M offering
Seeking Alpha · 04/02 11:35
Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases
Benzinga · 04/02 11:13
Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients With Microsatellite Stable Colorectal Cancer With Or Without Liver Metastases
Benzinga · 04/02 11:04
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Barchart · 04/02 06:01
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.